PL367821A1 - Inhibitory proteaz cysteinowych o strukturze 2-cyjano-4-amino-pirymidyny wykazujące aktywność inhibitorów katepsyny K do leczenia chorób zapalnych i innych - Google Patents

Inhibitory proteaz cysteinowych o strukturze 2-cyjano-4-amino-pirymidyny wykazujące aktywność inhibitorów katepsyny K do leczenia chorób zapalnych i innych

Info

Publication number
PL367821A1
PL367821A1 PL02367821A PL36782102A PL367821A1 PL 367821 A1 PL367821 A1 PL 367821A1 PL 02367821 A PL02367821 A PL 02367821A PL 36782102 A PL36782102 A PL 36782102A PL 367821 A1 PL367821 A1 PL 367821A1
Authority
PL
Poland
Prior art keywords
cathepsin
diseases
treatment
inflammations
cyano
Prior art date
Application number
PL02367821A
Other languages
English (en)
Other versions
PL208280B1 (pl
Inventor
Eva Altmann
Kenji Hayakawa
Genji Iwasaki
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0121026.9A external-priority patent/GB0121026D0/en
Priority claimed from GB0121024A external-priority patent/GB0121024D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL367821A1 publication Critical patent/PL367821A1/pl
Publication of PL208280B1 publication Critical patent/PL208280B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL367821A 2001-08-30 2002-08-29 Związki stanowiące inhibitory proteaz cysteinowych wykazujące aktywność inhibitorów katepsyny K, kompozycje farmaceutyczne zawierające takie związki, zastosowanie wspomnianych związków oraz sposób otrzymywania takich związków PL208280B1 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0121026.9A GB0121026D0 (en) 2001-08-30 2001-08-30 Organic compounds
GB0121024A GB0121024D0 (en) 2001-08-30 2001-08-30 Organic compounds
PCT/EP2002/009661 WO2003020278A1 (en) 2001-08-30 2002-08-29 Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin k inhibitory activity for the treatment of inflammations and other diseases

Publications (2)

Publication Number Publication Date
PL367821A1 true PL367821A1 (pl) 2005-03-07
PL208280B1 PL208280B1 (pl) 2011-04-29

Family

ID=26246490

Family Applications (1)

Application Number Title Priority Date Filing Date
PL367821A PL208280B1 (pl) 2001-08-30 2002-08-29 Związki stanowiące inhibitory proteaz cysteinowych wykazujące aktywność inhibitorów katepsyny K, kompozycje farmaceutyczne zawierające takie związki, zastosowanie wspomnianych związków oraz sposób otrzymywania takich związków

Country Status (22)

Country Link
US (2) US7112589B2 (pl)
EP (1) EP1423121B1 (pl)
JP (1) JP4131701B2 (pl)
KR (1) KR100629834B1 (pl)
CN (1) CN1549717B (pl)
AR (1) AR036375A1 (pl)
AT (1) ATE345136T1 (pl)
AU (1) AU2002333758B2 (pl)
BR (1) BR0212141A (pl)
CA (1) CA2456127C (pl)
CO (1) CO5560576A2 (pl)
DE (1) DE60216122T2 (pl)
ES (1) ES2275946T3 (pl)
HU (1) HUP0401431A3 (pl)
IL (1) IL160295A0 (pl)
MX (1) MXPA04001930A (pl)
NZ (1) NZ531287A (pl)
PE (1) PE20030772A1 (pl)
PL (1) PL208280B1 (pl)
PT (1) PT1423121E (pl)
RU (1) RU2326119C2 (pl)
WO (1) WO2003020278A1 (pl)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR036375A1 (es) * 2001-08-30 2004-09-01 Novartis Ag Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos
SE0201980D0 (sv) 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
SE0201976D0 (sv) * 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
GB0220187D0 (en) * 2002-08-30 2002-10-09 Novartis Ag Organic compounds
US20060281714A1 (en) * 2003-07-21 2006-12-14 Johann Zimmermann Combinations of a cathepsin k inhibitor and a bisphosphonate in the treatment of bone metastasis, tumor growth and tumor-induced bone loss
WO2005011703A1 (en) * 2003-08-04 2005-02-10 Akzo Nobel N.V. 2-cyano-1,3,5-triazine-4,6-diamine derivatives
WO2005030128A2 (en) * 2003-09-23 2005-04-07 Merck & Co., Inc. Pyrazole modulators of metabotropic glutamate receptors
KR20060107792A (ko) * 2003-11-19 2006-10-16 노파르티스 아게 중증 골 소실 질환의 치료를 위한 카텝신 ｋ 억제제의 용도
US20070232586A1 (en) * 2004-04-21 2007-10-04 Kazuyuki Ohmoto Hydrazino-Substituted Heterocyclic Nitrile Compounds and Use Thereof
TW200614993A (en) 2004-06-11 2006-05-16 Akzo Nobel Nv 4-phenyl-pyrimidine-2-carbonitrile derivatives
TW200624429A (en) * 2004-09-07 2006-07-16 Glaxo Group Ltd Novel cysteine protease inhibitors
WO2006040300A1 (en) * 2004-10-12 2006-04-20 N.V. Organon 4-cycloalkyl-pyrimidine-2-carbonitrile derivatives
IL164942A0 (en) * 2004-10-31 2005-12-18 Yeda Res & Dev The use of a protease or a protease inhibitor for the manufacture of medicaments
GB0514684D0 (en) * 2005-07-18 2005-08-24 Novartis Ag Organic compounds
CA2617725C (en) * 2005-08-05 2012-04-03 Hybrigenics Sa Novel cysteine protease inhibitors and their therapeutic applications
AR057110A1 (es) * 2005-09-02 2007-11-14 Glaxo Group Ltd DERIVADOS DE HETEROARIL-NITRILOS SUSTITUíDOS QUE SON INHIBIDORES DE PROTEASAS
US7326715B2 (en) 2005-09-23 2008-02-05 N.V. Organon 4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives
TW200745055A (en) * 2005-09-23 2007-12-16 Organon Nv 4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives
US7687515B2 (en) 2006-01-17 2010-03-30 N.V. Organon 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
CA2652600A1 (en) * 2006-05-22 2007-11-29 Velcura Therapeutics, Inc. Use of cathepsin k antagonists in bone production
JP2009541284A (ja) * 2006-06-23 2009-11-26 アストラゼネカ・アクチエボラーグ プテリジン誘導体およびカテプシン阻害剤としてのそれらの使用
EP1947091A1 (en) * 2007-01-16 2008-07-23 Glaxo Group Limited Pyrimidyl nitrile derivatives as cysteine protease inhibitors
US7932251B2 (en) 2007-07-16 2011-04-26 N.V. Organon 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
US8354446B2 (en) 2007-12-21 2013-01-15 Ligand Pharmaceuticals Incorporated Selective androgen receptor modulators (SARMs) and uses thereof
EP2719700A1 (en) 2008-01-09 2014-04-16 Amura Therapeutics Limited Tetrahydrofuro(3,2-b)pyrrol-3-one derivatives as inhibitors of cysteine proteinases
TW201035094A (en) 2009-01-16 2010-10-01 Organon Nv 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
US8026236B2 (en) 2009-01-16 2011-09-27 N.V. Organon 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
EP2316820A1 (en) * 2009-10-28 2011-05-04 Dompe S.p.A. 2-aryl-propionamide derivatives useful as bradykinin receptor antagonists and pharmaceutical compositions containing them
WO2011086125A1 (en) 2010-01-15 2011-07-21 N.V. Organon 1H-[1,2,3]TRIAZOLO[4,5-c]PYRIDINE-4-CARBONITRILE DERIVATIVES
DK2626431T3 (en) 2010-10-06 2015-12-21 Fundació Inst De Recerca Biomèdica Irb Barcelona A process for the diagnosis, prognosis and treatment of breast cancer metastasis
US8524710B2 (en) * 2010-11-05 2013-09-03 Hoffmann-La Roche Inc. Pyrrolidine derivatives
EP2650682A1 (en) 2012-04-09 2013-10-16 Fundació Privada Institut de Recerca Biomèdica Method for the prognosis and treatment of cancer metastasis
EP2859120B1 (en) 2012-06-06 2018-11-14 Fundació Institut de Recerca Biomèdica (IRB Barcelona) Method for the diagnosis and prognosis of lung cancer metastasis
ES2744244T3 (es) 2012-10-12 2020-02-24 Inbiomotion Sl Método para el diagnóstico, pronóstico y tratamiento de metástasis de cáncer de próstata usando c-MAF
US10119171B2 (en) 2012-10-12 2018-11-06 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
US20160032399A1 (en) 2013-03-15 2016-02-04 Inbiomotion S.L. Method for the Prognosis and Treatment of Renal Cell Carcinoma Metastasis
AU2014229505B2 (en) 2013-03-15 2020-02-27 Fundacio Institut De Recerca Biomedica (Irb Barcelona) Method for the prognosis and treatment of cancer metastasis
MX362041B (es) 2013-10-09 2019-01-07 Fundacio Inst De Recerca Biomedica Irb Barcelona Método para el pronóstico y tratamiento de cáncer metastásico de los huesos originado de cáncer de mama.
EP3613418A1 (en) 2014-01-17 2020-02-26 Ligand Pharmaceuticals, Inc. Methods and compositions for modulating hormone levels
CA2967224C (en) 2014-12-11 2023-08-22 Inbiomotion S.L. Binding members for human c-maf
KR20230128144A (ko) 2016-05-25 2023-09-01 인바이오모션 에스.엘. c-MAF 상태에 기초한 유방암의 치료
KR20190112009A (ko) * 2017-01-27 2019-10-02 장피트 Ror감마 조절제 및 이의 용도
CN108586356B (zh) * 2017-03-16 2021-02-19 杭州科巢生物科技有限公司 瑞博西尼新中间体及其制备瑞博西尼的合成方法
CA3082728A1 (en) 2017-11-22 2019-05-31 Inbiomotion S.L. Therapeutic treatment of breast cancer based on c-maf status
CN109467536B (zh) * 2018-12-23 2020-06-05 沧州普瑞东方科技有限公司 2-氯/羟基嘧啶-5-羧酸的合成方法
WO2020201572A1 (en) 2019-04-05 2020-10-08 Université De Bretagne Occidentale Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1251074B (de) 1960-11-02 1967-09-28 J R Geigy A -G , Basel (Schweiz) Selektives Herbizid
NL295648A (pl) * 1962-07-26
BR6915234D0 (pt) 1969-05-22 1973-06-07 American Cyanamid Co Novos derivados de melamina e processo para sua preparaca
CH627919A5 (de) * 1977-04-14 1982-02-15 Ciba Geigy Ag Herbizide mittel.
EP0850228A1 (en) * 1995-09-01 1998-07-01 Signal Pharmaceuticals, Inc. Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions
US6313127B1 (en) 1996-02-02 2001-11-06 Zeneca Limited Heterocyclic compounds useful as pharmaceutical agents
DE19817459A1 (de) 1998-04-20 1999-10-21 Basf Ag Neue heterozyklische substituierte Amide, Herstellung und Anwendung
DE60003702T2 (de) 1999-09-13 2004-04-22 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield Heterocyclische verbindungen als reversible inhibitoren von cysteinproteasen
CN1374953A (zh) * 1999-09-16 2002-10-16 田边制药株式会社 含氮的6－员芳香环化合物
CN1657523A (zh) 2000-04-28 2005-08-24 田边制药株式会社 环状化合物
GB0013383D0 (en) 2000-06-01 2000-07-26 Glaxo Group Ltd Therapeutic benzamide derivatives
AR036375A1 (es) * 2001-08-30 2004-09-01 Novartis Ag Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos
SE0201980D0 (sv) 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
SE0201976D0 (sv) 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
US20040249153A1 (en) 2004-12-09
PL208280B1 (pl) 2011-04-29
WO2003020278A1 (en) 2003-03-13
NZ531287A (en) 2005-12-23
CO5560576A2 (es) 2005-09-30
HUP0401431A3 (en) 2004-11-29
DE60216122D1 (de) 2006-12-28
BR0212141A (pt) 2004-08-24
HUP0401431A2 (hu) 2004-10-28
IL160295A0 (en) 2004-07-25
CA2456127C (en) 2009-10-20
PT1423121E (pt) 2007-02-28
DE60216122T2 (de) 2007-09-06
US7112589B2 (en) 2006-09-26
EP1423121B1 (en) 2006-11-15
RU2004109812A (ru) 2005-10-20
MXPA04001930A (es) 2004-06-15
PE20030772A1 (es) 2003-10-02
US20060074092A1 (en) 2006-04-06
CN1549717B (zh) 2011-08-17
AU2002333758B2 (en) 2006-01-19
KR100629834B1 (ko) 2006-09-29
ES2275946T3 (es) 2007-06-16
EP1423121A1 (en) 2004-06-02
RU2326119C2 (ru) 2008-06-10
ATE345136T1 (de) 2006-12-15
JP2005505550A (ja) 2005-02-24
CA2456127A1 (en) 2003-03-13
KR20040029101A (ko) 2004-04-03
AR036375A1 (es) 2004-09-01
CN1549717A (zh) 2004-11-24
JP4131701B2 (ja) 2008-08-13

Similar Documents

Publication Publication Date Title
MXPA04001930A (es) Inhibidores de proteasa de cisteina con estructura de 2-ciano-4amino-pirimidina y actividad inhibidora de catepsina k para el tratamiento de inflaciones y otras enfermedades.
GB0121033D0 (en) Organic compounds
GB0220187D0 (en) Organic compounds
DK1601677T3 (da) Spirosubstituerede pyrrolopyrimidiner
EP1562897A4 (en) PHENYL ACARBOXAMIDE AS A BETA SEKRETASE INHIBITOR FOR THE TREATMENT OF ALZHEIMER
NO20030895D0 (no) Ny anvendelse av dipeptidyl peptidase IV inhibitorer
DK1480961T3 (da) Glutaminylbaserede DPIV-inhibitorer
IN2005KO00312A (pl)
GB0223040D0 (en) Therapeutic compounds
NZ526913A (en) Inhibitors of cruzipain and other cysteine proteases
GB0112348D0 (en) Compounds
SE0202429D0 (sv) Novel Compounds
SE0301232D0 (sv) Novel use
SG162614A1 (en) Bicyclic 6-alkylidene-penems as beta-lactamases inhibitors
WO2001034565A3 (en) Protease inhibitors
MXPA04005809A (es) Inhibidores de proteinas quinasas.
WO2001034566A3 (en) Protease inhibitors
MY128242A (en) Hallogenated aminobenzophenones and aminobenzoylpyridines as inhibitors of il-1 and tnf
IS8498A (is) Notkun katepsín K tálma til að meðhöndla alvarlega beintapssjúkdóma
ECSP044989A (es) Inhibidores de proteasa de cisteina con estructura de 2-ciano-4-amino-pirimidina y actividad inhibidora de catepsina k para el tratamiento de inflamaciones y otras enfermedades
MXPA04003938A (es) Compuestos retinoides heterociclicos.
WO2002023784A3 (en) Cysteine protease inhibitors
AU2002254907A1 (en) Diamides which inhibit tryptase and factor xa activity
MXPA04005310A (es) Inhibidores de fosfolipasa a2 citosolica.

Legal Events

Date Code Title Description
LAPS Decisions on the lapse of the protection rights

Effective date: 20130829